Autologous Bone Marrow Cell Treatment in Peripheral Atherosclerosis
The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2006 by University of Naples.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
University of Naples
Information provided by:
University of Naples
ClinicalTrials.gov Identifier:
NCT00306085
First received: March 14, 2006
Last updated: March 21, 2006
Last verified: March 2006
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Implantation of bone marrow cells, including endothelial progenitor cells, into ischemic limbs has been shown to improve collateral vessel formation. In the present study the safety and feasibility of autologous blood mononuclear cells implantation will be investigated in patients with severe peripheral atherosclerosis.Twenty cases will be enrolled. Improvement in the ankle-brachial pressure index (ABI:>0.1), ischemic ulcers and angiography as well as laser doppler flow will be evaluated until six months.
| Condition | Intervention | Phase |
|---|---|---|
|
Peripheral Vascular Diseases |
Genetic: Autologous bone marrow cells |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | Autologous Bone Marrow Cell Treatment in Patients With Peripheral Atherosclerosis |
Resource links provided by NLM:
Further study details as provided by University of Naples:
Primary Outcome Measures:
- Clinical and instrumental indexes of functional impairment of peripheral atherosclerosis.
Secondary Outcome Measures:
- Angiographic and laser doppler measurements after six months from treatment.
| Estimated Enrollment: | 20 |
| Study Start Date: | April 2005 |
| Estimated Study Completion Date: | April 2006 |
Eligibility| Ages Eligible for Study: | 45 Years to 90 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Clinical diagnosis of third or fourth class of peripheral atherosclerosis
Exclusion Criteria:
- Insuline dependent diabetes
- Cancer
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00306085
Contacts
| Contact: Heidi Eisele | +39 081/5665685 | heidi.eisele@unina2.it |
Locations
| Italy | |
| University of Naples | Recruiting |
| Naples, Italy, 80134 | |
| Contact: Maria Carmela Corbisiero +39081/5665681 marika_corbi@inwind.it | |
Sponsors and Collaborators
University of Naples
Investigators
| Study Director: | Vincenzo Sica | University of Naples |
More Information
No publications provided by University of Naples
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00306085 History of Changes |
| Other Study ID Numbers: | 1 |
| Study First Received: | March 14, 2006 |
| Last Updated: | March 21, 2006 |
| Health Authority: | Italy: Ministry of Health |
Keywords provided by University of Naples:
|
Peripheral arterial disease, blood marrow cells, therapeutic angiogenesis. |
Additional relevant MeSH terms:
|
Atherosclerosis Vascular Diseases Peripheral Vascular Diseases Peripheral Arterial Disease |
Arteriosclerosis Arterial Occlusive Diseases Cardiovascular Diseases |
ClinicalTrials.gov processed this record on May 23, 2013